Search

Your search keyword '"van den Berkmortel, Franchette"' showing total 507 results

Search Constraints

Start Over You searched for: Author "van den Berkmortel, Franchette" Remove constraint Author: "van den Berkmortel, Franchette"
507 results on '"van den Berkmortel, Franchette"'

Search Results

1. Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial

3. Deep learning on CT scans to predict checkpoint inhibitor treatment outcomes in advanced melanoma

4. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

5. Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model

6. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma

7. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

8. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

9. High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial

10. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

11. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

12. Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

13. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

14. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

15. CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma

16. Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting

17. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry

18. Adjuvant treatment for melanoma in clinical practice – Trial versus reality

19. Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study

20. Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry

21. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy

22. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

23. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors

24. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.

25. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

26. Survival outcomes of patients with advanced mucosal melanoma diagnosed from 2013 to 2017 in the Netherlands – A nationwide population-based study

27. Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting

28. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study

29. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

30. Lower risk of severe checkpoint inhibitor toxicity in more advanced disease

31. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

32. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

33. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma

34. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

35. Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study

36. Long-Term Survival in Patients With Advanced Melanoma

37. Adjuvant treatment with anti-PD-1 in acral melanoma:A nationwide study

38. Long-Term Survival in Patients With Advanced Melanoma

39. BRAF/MEK inhibitor rechallenge in advanced melanoma patients

40. A prediction model for response to immune checkpoint inhibition in advanced melanoma

41. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

42. A prediction model for response to immune checkpoint inhibition in advanced melanoma

43. BRAF/MEK inhibitor rechallenge in advanced melanoma patients

44. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

45. Improving survival in advanced melanoma patients:a trend analysis from 2013 to 2021

46. The impact of colorectal surgery on health-related quality of life in older functionally dependent patients with cancer – A longitudinal follow-up study

47. BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma

48. A prediction model for response to immune checkpoint inhibition in advanced melanoma

49. BRAF/MEK inhibitor rechallenge in advanced melanoma patients

Catalog

Books, media, physical & digital resources